D-1326-2016 Class II Terminated

Recalled by Pharmakon Pharmaceuticals, Inc. — Noblesville, IN

FDA drug recall D-1326-2016 was initiated by Pharmakon Pharmaceuticals, Inc. on Apr 20, 2016 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Jan 11, 2018). Affected quantity: 120.

Recall details

Product Type
Drugs
Report Date
Jul 20, 2016
Initiation Date
Apr 20, 2016
Termination Date
Jan 11, 2018
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
120

Product description

HYDROmorphone HCI 0.2 mg/mL in 0.9% Sodium Chloride 50 mL fill in a 60 mL Monoject Syringe, Rx Only, Compounded by PHARMAKON Pharmaceuticals, Noblesville, IN 46060, NDC 45183-0933-75

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

Nationwide VA/DOD: CA, KY, MD, NC, OK, TX, VA

Code information

All Sterile Compounded Products within Expiry

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1326-2016
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Pharmakon Pharmaceuticals, Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-1326-2016. Report a data issue: hello@regdatalab.com.